2-63856320-A-G
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_001001521.2(UGP2):c.1A>G(p.Met1?) variant causes a start lost change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000384 in 1,612,832 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_001001521.2 start_lost
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000328 AC: 5AN: 152210Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000561 AC: 14AN: 249502Hom.: 0 AF XY: 0.0000742 AC XY: 10AN XY: 134860
GnomAD4 exome AF: 0.0000390 AC: 57AN: 1460622Hom.: 0 Cov.: 30 AF XY: 0.0000592 AC XY: 43AN XY: 726610
GnomAD4 genome AF: 0.0000328 AC: 5AN: 152210Hom.: 0 Cov.: 32 AF XY: 0.0000538 AC XY: 4AN XY: 74358
ClinVar
Submissions by phenotype
Developmental and epileptic encephalopathy, 83 Pathogenic:9
- -
This homozygous start loss variant identified in 7 month female with refractory seizure, pneumonia, GDD with west syndrome. This nucleotide change has an allele frequency of 0.0053% in gnomAD aggregate database [PM2]. This variant has a clinvar entry with Pathogenic/Likely Pathogenic interpretation by multiple submitter [PP5]. Clinvar variation ID: 805980. PMID: 31820119. Based on available evidence the variant is classified as "Pathogenic". -
- -
The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.005%). Predicted Consequence/Location: Missense changes are a common disease-causing mechanism. Functional studies provide moderate evidence of the variant having a damaging effect on the gene or gene product (PMID: 31820119). In silico tool predictions suggest no damaging effect of the variant on gene or gene product [REVEL: 0.17 (<0.4); 3Cnet: 0.06 (<0.15, specificity 0.78 and negative predicitive value 0.92)]. Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000805980 /PMID: 31820119).The variant has been reported to be in trans with a pathogenic variant as either compound heterozygous or homozygous in at least 2 similarly affected unrelated individuals (PMID: 31820119). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline. -
Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0106 - This gene is associated with autosomal recessive disease. (I) 0206 - Variant is predicted to result in a loss of the canonical translation initiation codon (ATG). (SP) 0252 - This variant is homozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (15 heterozygotes, 0 homozygotes). (SP) 0705 - No comparable variants have previous evidence for pathogenicity. (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported in 22 individuals from 15 families (PMID: 31820119). (SP) 1002 - This variant has moderate functional evidence supporting abnormal protein function. The absence of the shorter isoform leads to a reduction of functional UGP2 enzyme in neural stem cells and leads to altered glycogen metabolims (PMID: 31820119). (SP) 1102 - Strong phenotype match for this individual. (SP) 1209 - This variant has been shown to be both maternally and paternally inherited (biallelic) by trio analysis. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign -
- -
- -
The missense variant p.M12V in UGP2 (NM_006759.3) has been previously reported as a recurrent homozygous mutation in similarly affected patients (Perenthaler E et al). The variant causes a disruption of the start codon of the shorter isoform, which is predominant in brain and hence leads to disease as proved by functional studies on zebrafish (Perenthaler E et al). The p.M12V variant is observed in 12/30,282 (0.0396%) alleles from individuals of South Asian background in gnomAD Exomes and is novel (not in any individuals) in 1000 Genomes. It has been submiited to ClinVar as Pathogenic. For these reasons, this variant has been classified as Pathogenic. -
PS3,PP1,PM3(strong),PM2,PP3 -
D-6618 Pathogenic:1
Homozygous missense variation in exon 2 of UGP2 gene that result in the amino acid substitution of caline for methionine at codon 21 was detected. The in silico prediction of the variant is benign by PolyPhen-2 (HumDiv), SIFT, LRT and MutationTaster2. The reference codon is conserved across species. In summary, the variant meets our criteria to be classified as a variant of uncertain significance. -
not provided Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. This sequence change replaces methionine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 12 of the UGP2 protein (p.Met12Val). This variant is present in population databases (rs768305634, gnomAD 0.04%). This missense change has been observed in individuals with clinical features of UGP2-related developmental and epileptic encephalopathy (PMID: 31820119; Invitae). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 805980). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. Experimental studies have shown that this missense change affects UGP2 function (PMID: 31820119). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at